ESSA Pharma Inc.
EPIXDelisted Oct 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001633932
ESSA Pharma Inc. was delisted on Oct 9, 2025; its insiders filed their last Form 4 on Oct 15, 2025; 32 institutions reported holding it in 13F filings for Q3 2025, worth $4.30M in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in ESSA Pharma Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- 0 vs. Q1 2025
- Shares held
- 31.0M
- −710.6K (−2.2%) vs. Q1 2025
- Total value
- $52.7M
- +$2.59M (+5.2%) vs. Q1 2025
- New holders
- 4
- 7 more added
- Sold out
- 4
- 9 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EPIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 32 | $4.30M |
| Q2 2025 | 36 | $52.7M |
| Q1 2025 | 36 | $50.1M |
| Q4 2024 | 45 | $58.8M |
| Q3 2024 | 32 | $212.7M |
| Q2 2024 | 31 | $185.1M |
| Q1 2024 | 33 | $297.5M |
| Q4 2023 | 31 | $229.4M |
| Q3 2023 | 36 | $103.4M |
| Q2 2023 | 39 | $89.8M |
| Q1 2023 | 37 | $98.3M |
| Q4 2022 | 45 | $84.1M |
| Q3 2022 | 54 | $62.2M |
| Q2 2022 | 59 | $119.0M |
| Q1 2022 | 70 | $229.9M |
| Q4 2021 | 60 | $530.1M |
| Q3 2021 | 75 | $297.4M |
| Q2 2021 | 80 | $976.0M |
| Q1 2021 | 70 | $895.7M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding ESSA Pharma Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Barclays PLC | 355 | $604 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 817 | $1.00K | 0.00% | 00.0% | Unchanged |
| TD Waterhouse Canada Inc. | 900 | $1.53K | 0.00% | 00.0% | Unchanged |
| CIBC Private Wealth Group, LLC | 2,500 | $4.25K | 0.00% | 00.0% | Unchanged |
| Truvestments Capital LLC | 3,688 | $6.27K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 4,050 | $6.88K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 6,000 | $10.2K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,074 | $12.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 12,021 | $20.4K | 0.00% | −11,587−49.1% | Reduced |
| Schonfeld Strategic Advisors LLC | 14,343 | $24.4K | 0.00% | −8,500−37.2% | Reduced |
| Geode Capital Management, LLC | 23,840 | $40.5K | 0.00% | −3,018−11.2% | Reduced |
| Shay Capital LLC | 24,348 | $41.4K | 0.01% | −283−1.1% | Reduced |
| Lepercq De Neuflize Asset Management LLC | 33,700 | $57.3K | 0.05% | +2,000+6.3% | Added |
| XTX Topco Ltd | 42,173 | $71.7K | 0.00% | +19,344+84.7% | Added |
| Jane Street Group, LLC | 43,907 | $74.6K | 0.00% | +43,907 | New |
| American Century Companies Inc | 46,373 | $78.8K | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 50,000 | $85.0K | 0.01% | +50,000 | New |
| Citadel Advisors LLC | 54,039 | $91.9K | 0.00% | −28,084−34.2% | Reduced |
| Magnus Financial Group LLC | 55,206 | $93.8K | 0.01% | 00.0% | Unchanged |
| Group One Trading, L.P. | 83,823 | $142.5K | 0.00% | +62,705+296.9% | Added |
| Rangeley Capital, LLC | 170,000 | $289.0K | 0.36% | +170,000 | New |
| JPMorgan Chase & Co | 189,094 | $321.5K | 0.00% | +24,219+14.7% | Added |
| LMR Partners LLP | 200,000 | $340.0K | 0.01% | +200,000 | New |
| Two Sigma Investments, LP | 222,327 | $378.0K | 0.00% | −56,793−20.3% | Reduced |
| Two Sigma Advisers, LP | 260,800 | $443.4K | 0.00% | −15,300−5.5% | Reduced |
| BNP Paribas Arbitrage, SA | 271,195 | $461.0K | 0.00% | +35,794+15.2% | Added |
| DLD Asset Management, LP | 314,968 | $535.4K | 0.06% | +131,310+71.5% | Added |
| Aldebaran Capital, LLC | 578,939 | $984.2K | 0.97% | +9,645+1.7% | Added |
| Bank of America Corp | 627,930 | $1.07M | 0.00% | −70,338−10.1% | Reduced |
| Pfizer Inc | 1,675,000 | $2.85M | 0.49% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,209,998 | $3.76M | 0.76% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 2,262,026 | $3.85M | 0.27% | 00.0% | Unchanged |
| Morgan Stanley | 4,209,670 | $7.16M | 0.00% | −90,098−2.1% | Reduced |
| BML Capital Management, LLC | 4,221,546 | $7.18M | 5.50% | 00.0% | Unchanged |
| Tang Capital Management LLC | 4,300,000 | $7.31M | 0.37% | 00.0% | Unchanged |
| BVF Inc | 8,748,629 | $14.9M | 0.53% | 00.0% | Unchanged |
| Altium Capital Management LP | 0 | $0 | 0.00% | −1,050,369−100.0% | Sold out |
| Deuterium Capital Management, LLC | 0 | $0 | 0.00% | −110,412−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −14,115−100.0% | Sold out |
| Laurel Wealth Advisors LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |